^
Association details:
Biomarker:EWSR1-CREM fusion
Cancer:Sarcoma
Drug:pazopanib (Multi-tyrosine kinase inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
Title:

Case report: The activity of multi-kinase VEGF inhibitor, Pazopanib, in metastatic undifferentiated round cell sarcomas harboring EWSR1::CREM fusion: clinicopathological series of two cases and literature review

Published date:
09/27/2023
Excerpt:
A 49-year-old man with a past medical history of sarcoma...Tumoral whole transcriptome sequencing identified an EWSR1::CREM fusion...He completed 13 cycles of VIT after which he presented progression of the disease and switched to monotherapy with Pazopanib (Figure 1E). He has undergone imaging every 3 months consistent with stable disease of at least 28 months...
DOI:
https://doi.org/10.3389/fonc.2023.1215003